These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 18046224

  • 1. Predicted biologic activity of intravitreal bevacizumab.
    Stewart MW.
    Retina; 2007; 27(9):1196-200. PubMed ID: 18046224
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF.
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
    Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M.
    Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
    [Abstract] [Full Text] [Related]

  • 8. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, Hashiguchi T, Maruyama I, Sakamoto T.
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [Abstract] [Full Text] [Related]

  • 9. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion.
    Chuang LH, Wu WC, Yeung L, Wang NK, Hwang YS, Chen KJ, Kuo JZ, Lai CC.
    Ophthalmic Res; 2011 May; 45(1):31-5. PubMed ID: 20714188
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
    Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T.
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
    [Abstract] [Full Text] [Related]

  • 11. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans.
    Meyer CH, Krohne TU, Holz FG.
    Retina; 2011 Oct; 31(9):1877-84. PubMed ID: 21738089
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of intravitreal bevacizumab (Avastin).
    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ.
    Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
    Hattori T, Shimada H, Nakashizuka H, Mizutani Y, Mori R, Yuzawa M.
    Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802
    [Abstract] [Full Text] [Related]

  • 16. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes.
    Wu WC, Lai CC, Chen KJ, Chen TL, Wang NK, Hwang YS, Yeung L, Li LM.
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3701-8. PubMed ID: 20181842
    [Abstract] [Full Text] [Related]

  • 17. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
    Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N.
    Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR, Del Priore LV.
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.